Researchers report on the use of genetically modified stem cells to generate new muscle fibers and improve disease-associated muscle function and phenotype in a mouse model of Duchenne muscular dystrophy (DMD).
The vision of the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) is to extend and improve the function, quality of life and life span for all individuals diagnosed with DMD. This program is administered by the US Army Medical Research and Materiel Command through the Office of the Congressionally Directed Medical Research Programs (CDMRP).
Liestal, Switzerland, August 24, 2011 – Santhera Pharmaceuticals (SIX: SANN) announced today that the United States Patent and Trademark Office granted patent protection for the use of idebenone (brand name CatenaÂ®) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies. The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.
A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD114044)
The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
A discovery that strengthens the bodyâ€™s ability to repair muscle tissue could lead to new treatments for people with muscular dystrophy and other degenerative muscle diseases.
For years, scientists have tried to understand why children with Duchenne muscular dystrophy experience severe muscle wasting and eventual death.
Dystrophin absence in Duchenne muscular dystrophy (DMD) causes severe muscle degeneration. We describe that, as consequence of fibre damage, specific muscle-miRNAs are released into the bloodstream of DMD patients and their levels correlate with the severity of the disease.